These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38830885)

  • 1. The m6A reader HNRNPC promotes glioma progression by enhancing the stability of IRAK1 mRNA through the MAPK pathway.
    Chen JJ; Lu TZ; Wang T; Yan WH; Zhong FY; Qu XH; Gong XC; Li JG; Tou FF; Jiang LP; Han XJ
    Cell Death Dis; 2024 Jun; 15(6):390. PubMed ID: 38830885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT.
    Huang GZ; Wu QQ; Zheng ZN; Shao TR; Chen YC; Zeng WS; Lv XZ
    Aging (Albany NY); 2020 Jun; 12(12):11667-11684. PubMed ID: 32526707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression.
    Lv W; Tan Y; Xiong M; Zhao C; Wang Y; Wu M; Wu Y; Zhang Q
    J Transl Med; 2021 Dec; 19(1):527. PubMed ID: 34952600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
    Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
    J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HNRNPC promotes estrogen receptor-positive breast cancer cell cycle by stabilizing WDR77 mRNA in an m6A-dependent manner.
    Xu W; Huang Z; Xiao Y; Li W; Xu M; Zhao Q; Yi P
    Mol Carcinog; 2024 May; 63(5):859-873. PubMed ID: 38353359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The m6A reader HNRNPC predicts adverse prognosis and promotes the progression of colorectal cancer.
    Yu YM; Hu Y
    Technol Health Care; 2024; 32(3):1445-1453. PubMed ID: 37661903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
    Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
    Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.
    Chang YZ; Chai RC; Pang B; Chang X; An SY; Zhang KN; Jiang T; Wang YZ
    Cancer Lett; 2021 Jul; 511():36-46. PubMed ID: 33933553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.
    Miao YQ; Chen W; Zhou J; Shen Q; Sun Y; Li T; Wang SC
    Bioengineered; 2022 Jan; 13(1):1858-1871. PubMed ID: 35012429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5.
    Shi S; Wu T; Ma Z; Zhang X; Xu K; Tian Q; Gao L; Yin X; Xu S; Yang S
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4639-4651. PubMed ID: 36175801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-Methyladenosine reader HNRNPC-mediated downregulation of circITCH prevents miR-224-3p sequestering and contributes to tumorigenesis in nasopharyngeal carcinoma.
    Zhou Q; Song W; Li X; Lin J; Zhu C; Cao L; Li W; Lin S
    Environ Toxicol; 2024 May; 39(5):2893-2907. PubMed ID: 38299319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HNRNPC impedes m
    Huang XT; Li JH; Zhu XX; Huang CS; Gao ZX; Xu QC; Zhao W; Yin XY
    Cancer Lett; 2021 Oct; 518():196-206. PubMed ID: 34271104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
    Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression.
    Liu D; Luo X; Xie M; Zhang T; Chen X; Zhang B; Sun M; Wang Y; Feng Y; Ji X; Li Y; Liu B; Huang W; Xia L
    Cancer Sci; 2022 Oct; 113(10):3347-3361. PubMed ID: 35848884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
    Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
    Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4.
    Park YM; Hwang SJ; Masuda K; Choi KM; Jeong MR; Nam DH; Gorospe M; Kim HH
    Mol Cell Biol; 2012 Oct; 32(20):4237-44. PubMed ID: 22907752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis.
    Zheng Z; Zeng X; Zhu Y; Leng M; Zhang Z; Wang Q; Liu X; Zeng S; Xiao Y; Hu C; Pang S; Wang T; Xu B; Peng P; Li F; Tan W
    Mol Cancer; 2024 Jan; 23(1):4. PubMed ID: 38184608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β.
    Wang H; Yan X; Ji LY; Ji XT; Wang P; Guo SW; Li SZ
    Technol Cancer Res Treat; 2017 Aug; 16(4):497-511. PubMed ID: 26868851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-methylation of RNA-bound adenosine regulator HNRNPC promotes vascular endothelial dysfunction in type 2 diabetes mellitus by activating the PSEN1-mediated Notch pathway.
    Cai Y; Chen T; Wang M; Deng L; Li C; Fu S; Xie K
    Diabetes Res Clin Pract; 2023 Mar; 197():110261. PubMed ID: 36681355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells.
    Gu Z; Yang Y; Ma Q; Wang H; Zhao S; Qi Y; Li Y
    Respir Res; 2022 Dec; 23(1):362. PubMed ID: 36536402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.